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Abstract
Background: Vitamin D deficiency has been suggested as a cardiovascular risk factor, but little is known about underlying
mechanisms or associations with inflammatory or hemostatic markers. Our aim was to investigate the association between
25-hydroxyvitamin D [25(OH)D, a measure for vitamin D status] concentrations with pre-clinical variations in markers of
inflammation and hemostasis.
Methodology/Principal Findings: Serum concentrations of 25(OH)D, C-reactive protein (CRP), fibrinogen, D-dimer, tissue
plasminogen activator (tPA) antigen, and von Willebrand factor (vWF) were measured in a large population based study of
British whites (aged 45y). Participants for the current investigation were restricted to individuals free of drug treated
cardiovascular disease (n = 6538). Adjusted for sex and month, 25(OH)D was inversely associated with all outcomes
(p#0.015 for all), but associations with CRP, fibrinogen, and vWF were explained by adiposity. Association with tPA persisted
after full adjustment (body mass index, waist circumference, physical activity, TV watching, smoking, alcohol consumption,
social class, sex, and month), and average concentrations were 18.44% (95% CI 8.13, 28.75) lower for 25(OH)D $75 nmol/l
compared to ,25 nmol/l. D-dimer concentrations were lower for participants with 25(OH)D 50–90nmol/l compared to
others (quadratic term p= 0.01). We also examined seasonal variation in hemostatic and inflammatory markers, and
evaluated 25(OH)D contribution to the observed patterns using mediation models. TPA concentrations varied by season
(p= 0.02), and much of this pattern was related to fluctuations in 25(OH)D concentrations (p#0.001). Some evidence of a
seasonal variation was observed also for fibrinogen, D-dimer and vWF (p,0.05 for all), with 25(OH)D mediating some of the
pattern for fibrinogen and D-dimer, but not vWF.
Conclusions: Current vitamin D status was associated with tPA concentrations, and to a lesser degree with fibrinogen and
D-dimer, suggesting that vitamin D status/intake may be important for maintaining antithrombotic homeostasis.
Citation: Hyppo¨nen E, Berry D, Cortina-Borja M, Power C (2010) 25-Hydroxyvitamin D and Pre-Clinical Alterations in Inflammatory and Hemostatic Markers: A
Cross Sectional Analysis in the 1958 British Birth Cohort. PLoS ONE 5(5): e10801. doi:10.1371/journal.pone.0010801
Editor: Pieter H. Reitsma, Leiden University Medical Center, Netherlands
Received February 25, 2010; Accepted April 27, 2010; Published May 24, 2010
Copyright:  2010 Hyppo¨nen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the British Heart Foundation (PG/09/023). Data collection at age 44–46 years and statistical analyses were funded by the
UK Medical Research Council (MRC grants G0601653, G0000934), and 25(OH)D assays by the BUPA Foundation. E.H. is a Department of Health (UK) Public Health
Career Scientist. This work was undertaken at the Centre for Paediatric Epidemiology and Biostatistics which benefits from funding support from the MRC in its
capacity as the MRC Centre of Epidemiology for Child Health. Research at the University College London Institute of Child Health and Great Ormond Street
Hospital for Children NHS Trust benefits from R&D funding received from the NHS Executive. The funders had no role in study design, data collection and
analyses, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: e.hypponen@ich.ucl.ac.uk
Introduction
Vitamin D deficiency has been suggested to contribute to the
high and rising worldwide prevalence of cardiovascular disease
(CVD) [1]. Vitamin D is a hormone precursor, which before
exerting its metabolic effects undergoes two successive hydroxyl-
ations. The first hydroxylation converts vitamin D to 25-
hydroxyvitamin D [25(OH)D, which provides an indicator for
nutritional vitamin D status] [2] and the second to the main active
hormonal form, 1,25-dihydroxyvitamin D [1,25(OH)2D]. Hor-
monal vitamin D activity is found throughout human circulatory
tissue and 1,25(OH)2D production has been demonstrated in
endothelial cells of blood vessels [3] . Vitamin D receptors (VDR,
mediating the genomic hormonal actions) are expressed in
endothelial cells, cardiomyocytes and vascular smooth muscle
cells, including those in the coronary arteries [4,5]. VDR knockout
mice show signs of enhanced thrombogenicity [6].
The strongest evidence for a relation between vitamin D
metabolism and CVD risk has been obtained from clinical studies
reporting a marked reduction in mortality following administra-
tion of vitamin D analogues to patients with end-stage renal
disease [7,8,9]. Evidence for an association between vitamin D
status and subsequent risk of CVD was found in recent prospective
studies on myocardial infarction [10] and cardiovascular mortality
[11] ; both of these studies reported a two-fold increase in the risk
of CVD for vitamin D insufficient participants compared to others.
Concentration of the active hormone has been related to the
degree of arterial calcification in individuals at increased risk of
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myocardial infarction [12] and an inverse association has been
reported between serum 25(OH)D concentration with carotid
artery intima-media thickness [13], myocardial infarction [14],
metabolic syndrome [15,16], and CVD [17,18].
To date there is relatively little evidence from population-based
studies on the associations of 25(OH)D with indicators of
inflammation or hemostasis, and to what extent possible co-
variation is affected by adiposity. Obesity is a key determinant for
the circulating 25(OH)D concentrations [19] and also an
important cardiovascular risk factor. Consequently, it is difficult
to separate the effects of vitamin D status and adiposity when
evaluating their influences on cardiovascular risk. In order to
obtain further evidence for a possible independent contribution of
current vitamin D status on pre-clinical alterations in markers of
inflammation and hemostasis, we evaluated seasonal patterns in
inflammatory and hemostatic markers and the strength of the
effect mediation by 25(OH)D. This approach is likely to be
informative, as due to the strong influence of sun induced skin
synthesis, 25(OH)D concentrations vary greatly by season [19],
while little variation would be expected for adiposity. Our aim was
to investigate the association between 25(OH)D, adiposity (body
mass index, waist circumference) and pre-clinical variations in the
available risk markers (namely CRP, fibrinogen, D-dimer, tPA,
and von Willebrand factor). In these analyses, we used information
from the nationwide 1958 British birth cohort (1958BC) on over
6500 middle aged participants. We hypothesized that if vitamin D
intake affects the markers under investigation then further
evidence for an association should be obtained through analysing
the contribution of 25(OH)D to the seasonal variation in markers
of inflammation and hemostasis.
Results
The geometric mean of 25(OH)D concentration was
52.77 nmol/l (95% CI 52.18, 53.36). Table 1 shows the
distribution of 25(OH)D concentrations by social and lifestyle
characteristics. For both BMI and waist circumference (the
available adiposity indicators) the association with 25(OH)D was
non-linear (LRT curvature p#0.0001 and p= 0.04, respectively),
with the highest 25-hydoxyvitamin D concentrations observed for
individuals with normal weight (Figure 1). There was a steep
decline in the average 25(OH)D concentration by increasing
adiposity and a smaller reduction for the very lean.
Adjusted for sex and month of measurement only, 25(OH)D was
associated with all inflammatory and hemostatic outcomes (p#0.01
for CRP, fibrinogen, D-dimer and tPA, p= 0.015 for vWF,
Figure 2). Associations between 25(OH)D with CRP, fibrinogen,
and vWF were strongly attenuated after adjustment for lifestyle and
social indicators, and no evidence for an independent inverse
association remained after further adjustment for adiposity. For
fibrinogen, after full adjustment for adiposity, lifestyle and social
indicators, there was a curved association with some suggestion for
increased levels at 25(OH)D concentrations of $125 nmol/l (LRT
quadratic term p=0.06 Figure 2B). 25(OH)D had a curved
association with D-dimer, and after full adjustment participants
with 25(OH)D between 50–90 nmol/l tended to have lower levels
(LRT quadratic term p=0.01 Figure 2C). The association between
25(OH)D and tPA was not strongly affected by adjustment for
lifestyle factors, and a significant inverse trend was apparent after
further adjustment for adiposity although the effect size was halved
(Figure 2D). After full adjustment, participants with 25(OH)D
$75 nmol/l had on average 18.44% (95% CI 8.13, 28.75) lower
tPA concentrations compared to those with,25 nmol/l. There was
no evidence for effect modification by obesity on the association
between 25(OH)D and the inflammatory or hemostatic outcomes
(p.0.13 for all comparisons).
Given the strong influence of season on 25(OH)D concentra-
tions [19], we evaluated seasonal variation in hemostatic and
inflammatory markers, and tested mediation effects of 25(OH)D in
the observed patterns. Fibrinogen, tPA, D-dimer, and vWF but
not CRP had significant seasonal patterns (p=0.03, p=0.02,
p=0.02, p=0.01 and p=0.8, respectively, Figure 3). The strongest
effect mediation by 25(OH)D was seen in the pattern of tPA
(p,0.001), with 25(OH)D contributing to a lesser extent to
seasonal variation in D-dimer and fibrinogen. The seasonal
variation seen in vWF was not affected by 25(OH)D (p=0.99).
Discussion
We observed a strong cross-sectional association between
circulating 25(OH)D and tPA concentrations in participants free
of clinical CVD, and a seasonal pattern for tPA that was largely
mediated by 25(OH)D in this population. These findings, together
with the weaker evidence observed for a relation of 25(OH)D with
D-dimer and fibrinogen, suggest a role for current vitamin D status
in determining thrombolytic profile before progression to CVD.
A specific methodological challenge for these cross-sectional
analyses arose from the strong association of adiposity both with
25(OH)D concentrations and the inflammatory/hemostatic mark-
ers under study. In addition to the conventional approach of
evaluating the direct association between 25(OH)D and the
outcomes adjusting for potential confounders (most importantly,
body mass index and waist circumference), we evaluated seasonal
variation in the outcomes and the mediating influence of 25(OH)D
on the observed patterns. These analyses supported a relation of
25(OH)D with tPA, and interestingly, also to lesser extent with D-
dimer and fibrinogen. The seasonal pattern seen in vWF was not
affected by 25(OH)D, nor did we observe evidence for a direct
cross-sectional association, hence, this confirms the lack of
evidence for any association between vitamin D status and
circulating vWF concentrations in our study.
Comparison with other studies
Risk of myocardial infarction and other thrombotic complica-
tions is typically higher during the winter months than during the
summer [20,21], and in line with our study, fibrinogen (but not
CRP) has been reported to vary by season [22]. However, there is
little information on the direct associations between 25(OH)D and
circulating markers of hemostasis in apparently healthy adults. In
line with our findings, an earlier smaller study found the
association between 25(OH)D and CRP to be explained by
adiposity, while an independent relation persisted between
25(OH)D and tPA [23]. The lack of evidence for an association
between current vitamin D status and CRP agrees with recent
observations in other populations [24], including intervention
studies where vitamin D supplementation at varying dosages (700–
3332 IU per day) have failed to achieve changes in CRP
concentrations [25,26,27]. There is, however, one earlier inter-
vention which showed a significant (22%) fall in CRP following
vitamin D supplementation (50,000IU every three months over
one year) in vitamin D deficient British Bangladeshi adults [28]. It
is possible that associations between 25(OH)D and CRP might not
be detected in general population studies if effects are confined to
extreme vitamin D deficient groups.
Explanations
Increased concentrations of tPA and D-dimer are thought to
serve as markers for aggravated fibrinolytic activity reflecting
Vitamin D and Hemostasis
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10801
Table 1. Distribution of 25-hydroxyvitamin D concentration by background, lifestyle and social characteristics in the 1958 British
birth cohort.
25-hydroxyvitamin D, nmol/l
Number Geometric Mean* ,25 nmol/l .125 nmol/l
(%) (95%CI) %* (n) %* (n)
Sex
Men 3270 (50.0) 53.6 (52.8, 54.5) 6.2 (203) 1.4 (46)
Women 3268 (50.0) 51.9 (51.1, 52.8) 8.4 (273) 1.4 (45)
p-value 0.003 0.0007 0.9
Body Mass index
,25 2361 (36.1) 55.1 (54.0, 56.2) 7.5 (178) 2.2 (52)
25–30 2737 (41.9) 54.2 (53.3, 55.1) 5.8 (159) 1.2 (32)
.30 1440 (22.0) 46.8 (45.7, 47.9) 9.7 (139) 0.5 (7)
p-value #0.0001 0.04 #0.0001
Waist circumference**
Quartile 1 1642 (25.1) 57.4 (56.0, 58.7) 6.8 (111) 2.8 (46)
Quartile 2 1639 (25.1) 55.2 (54.0, 56.4) 6.2 (102) 1.8 (29)
Quartile 3 1627 (24.9) 52.6 (51.4, 53.7) 6.1 (100) 0.7 (11)
Quartile 4 1618 (24.8) 46.6 (45.6, 47.6) 9.9 (160) 0.2 (4)
Unknown 0.2 (12) 44.8 (29.4, 68.3) 25.0 (3) 8.3 (1)
p-value #0.0001 0.003 #0.0001
Vigorous activity
No 3206 (49.0) 49.6 (48.8, 50.4) 9.4 (300) 1.2 (37)
Yes 3236 (49.5) 56.3 (55.4, 57.2) 5.0 (163) 1.7 (54)
Unknown 96 (1.5) 48.0 (43.2, 53.2) 13.5 (13) 0.0 (0)
p-value #0.0001 #0.0001 0.07
TV watching/use of PC
,1 hours/day 745 (11.4) 56.3 (54.5, 58.2) 5.8 (43) 2.3 (17)
1–2 hours/day 3455 (52.8) 54.9 (54.1, 55.7) 5.5 (191) 1.6 (54)
$3 hours/day 2056 (31.4) 48.9 (47.9, 49.9) 9.9 (204) 0.9 (19)
Unknown 282 (4.3) 47.7 (44.9, 50.5) 13.5 (38) 0.4 (1)
p-value #0.0001 #0.0001 0.01
Smoking
None 3039 (46.5) 54.2 (53.3, 55.1) 6.1 (185) 1.3 (41)
Ex-smoker 1795 (27.5) 54.8 (53.7, 55.9) 5.1 (91) 1.3 (23)
1–19 per day 762 (11.7) 50.3 (48.5, 52.1) 10.4 (79) 1.7 (13)
$20 per day 720 (11.0) 45.5 (43.8, 47.2) 14.4 (104) 1.9 (14)
Unknown 222 (3.4) 51.8 (48.8, 55.1) 7.7 (17) 0.0 (0)
p-value #0.0001 #0.0001 0.2
Alcohol consumption
Non-drinker 378 (5.8) 46.1 (44.0, 48.4) 11.4 (43) 0.0 (0)
Light ,7 drinks/wk 3155 (48.3) 52.1 (51.3, 52.9) 7.5 (237) 1.0 (31)
Moderate 7–13 drinks/wk 1651 (25.3) 55.6 (54.4, 56.9) 5.6 (92) 1.8 (30)
Heavy 14–21 drinks/wk 746 (11.4) 55.9 (54.1, 57.8) 4.8 (36) 2.5 (19)
Very heavy .21 drinks/wk 590 (9.0) 49.7 (47.7, 51.8) 10.7 (63) 1.7 (10)
Unknown 18 ( 0.3) 41.5 (31.5, 54.6) 27.8 (5) 5.6 (1)
p-value 0.01 0.9 0.0003
Adult social class (2000){
I & II 2675 (40.9) 53.3 (52.4, 54.2) 6.7 (180) 1.4 (38)
III non-manual 1363 (20.9) 52.2 (50.9, 53.5) 7.9 (107) 1.1 (15)
III manual 1220 (18.7) 54.5 (53.1, 56.0) 6.1 (74) 2.0 (25)
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increased future burden of CVD [29]. Hence, the inverse
associations of 25(OH)D with tPA and D-dimer observed in our
study support the role of vitamin D metabolism in maintaining
antithrombotic homeostasis. The direct influences of hormonal
vitamin D axis on hemostasis are not well established, although
recent gene-expression studies suggest that vitamin D analogues
may suppress thrombogenicity and enhance fibrinolysis thereby
reducing intimal plaque formation [30,31]. Vitamin D analogues
have been observed to suppress PAI-1 expression in human
coronary artery smooth muscle cells [32]. Up regulation of PAI-1
has been associated with increased risk of CVD, and it has
been suggested that suppression of PAI-1 expression may
contribute to the observations on improved survival among
patients with chronic kidney disease who are taking vitamin D
analogues [7,32].
Hypovitaminosis D is believed to have wide-ranging influences
on vascular physiology, which include both direct (e.g. influences
on endothelial cells) and indirect pathways (endocrine, immuno-
modulatory) [33]. Vitamin D toxicity has been associated with
adverse effects on vascular calcification, but available data
indicates that calcification is increased also in hypovitaminosis D
[34,35]. Associations with increased blood pressure are believed to
be mediated through decreased renin production [36] and it has
been suggested that (independently of blood pressure), this could
also affect vascular stiffness [33]. Vitamin D might also exert anti-
proliferative effects on vascular smooth muscle cells, thereby
affecting myocardial cell hypertrophy and proliferation.
Discussion regarding optimal status for 25(OH)D concentration
is ongoing, and there is some debate about whether a threshold
exists [37,38,39,40]. The curved association between 25(OH)D
and D-dimer, together with the suggestive elevations in fibrinogen
and CRP at the extreme of high concentrations observed in this
study, could support a threshold effect with the optimal
concentration being between 60 and 120nmol/l. These results
are in line with an evaluation using data on multiple health
outcomes (including bone mineral density, lower extremity
function, risk of falls, fractures and colorectal cancer) [40], which
corresponds to an earlier consensus statement on osteoporosis [37]
suggesting 75nmol/l as the lower reference value. Earlier studies
have provided tentative evidence for a trend towards lower bone
mineral density and prolonged sit-to-stand time at a higher
extreme of 25(OH)D concentrations (.140 nmol/l) [40].
25-hydroxyvitamin D, nmol/l
Number Geometric Mean* ,25 nmol/l .125 nmol/l
(%) (95%CI) %* (n) %* (n)
IV & IV 1013 (15.5) 51.2 (49.8, 52.7) 8.0 (81) 1.0 (10)
Other 267 (4.1) 48.8 (45.9, 51.8) 12.7 (34) 1.1 (3)
p-value 0.007 0.02 0.8
*Values are n (%) or geometric mean. p-values from test for trend in linear or logistic regression adjusted for season and sex. Unknown values excluded.
**Waist circumference quartiles: for men; 65.4–90.6, 90.7–96.7, 96.8–103.5, 103.6–151.2 cm; for women; 56.2–75.8, 75.9–82.6, 82.7–91.6, 91.7–138.3 cm.




Figure 1. Variation in the average 25(OH)D concentration by body mass index (A) and waist circumference (B). Values are geometric
means (95% confidence intervals) standardized by sex.
doi:10.1371/journal.pone.0010801.g001
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Methodological considerations
The main strength of this study lies in the large sample of
participants, which provided adequate power for detailed
investigation of the associations between these inter-related health
indicators. Moreover, as data collection covered the full seasonal
range, we were able to obtain further support for the key findings
from the independent evaluation of seasonal patterns in inflam-
matory and hemostatic markers. Given the exceptional informa-
tion available from the 1958BC, we were able to adjust for
multiple factors in our analyses thereby controlling for confound-
ing introduced by demographic, lifestyle or social variations. Final
models evaluating the independent effect of 25(OH)D on
inflammatory and hemostatic outcomes were adjusted for
quadratic terms in both BMI and waist circumference in order
to control for adiposity as fully as possible. The full attenuation of
the association between 25(OH)D with CRP and fibrinogen after
adjustment for the available indicators suggests that these
measures were sufficient for this purpose.
Comparison between the effect of adjustment for 25(OH)D
concentrations in the observed seasonal patterns in the inflamma-
tory/hemostatic factors, and the direct associations between
25(OH)D and these outcomes, demonstrates the limitations of
cross-sectional analysis of data and the problem of possible over/
under adjustment. Given the strong influence of obesity on
25(OH)D concentrations, the latter would be expected to be
associated with any factor that is strongly related to obesity (given
a tolerable degree of measurement error and sufficient sample
size). This argues for the need to adjust for obesity fully to reduce
the likelihood of a false positive association due to confounding.
However, it could also be argued that adjustment for adiposity
may lead to an underestimation of associations between 25(OH)D
and inflammatory/hemostatic markers given that adiposity is a key
determinant for 25(OH)D [19]. Possible over-adjustment could
explain why we observed some evidence for effect mediation by
25(OH)D on our seasonal modeling of fibrinogen, while the
inverse relation seen in the unadjusted cross-sectional analyses
between these two factors was fully attenuated by the adjustment
for indicators of adiposity and lifestyle/social class.
Some further limitations need to be considered in relation to
these findings. Given the observational design, we cannot prove
causality or fully discount residual confounding by unmeasured
variations. Residual confounding may also affect our seasonal
mediation models; however, relevant confounders are likely to
differ given that potential factors presumed important for the
direct associations (such as adiposity) would not necessarily have
seasonal patterns. Although 25(OH)D is the best indicator for
vitamin D status in humans [2] information on serum parathyroid
levels or 1,25(OH)2D is not available and this precludes more
detailed investigation of vitamin D metabolism. Furthermore,
information was available only for the most commonly used CVD
risk markers, while other, perhaps more relevant, indicators were
not measured. Finally, although the 1958BC has been reported to
Figure 2. Variation in C-reactive protein (A), fibrinogen (B), D-
dimer (C), tissue plasminogen activator (D), and von Will-
ebrand factor (E) by 25(OH)D concentration. Model 1 (solid line):
adjusted for month of measurement and sex. Model 2 (dashed, short):
adjusted for lifestyle and social indicators (physical activity, time spent
watching TV/using PC, smoking, alcohol consumption and birth and
adult social class), month of measurement and sex. Model 3 (dashed,
long): adjusted for adiposity (BMI and waist circumference), lifestyle/
social indicators, month of measurement, and sex. Values are
coefficients from linear regression (reference ,25nmol/l), 95% confi-
dence intervals presented for Model 3 by the shaded area.
doi:10.1371/journal.pone.0010801.g002
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remain generally representative of the current UK population,
there is an underestimation of some minority groups [41]. These
analyses were restricted to individuals of white Caucasian origin,
which will reduce population stratification, however, generaliza-
tion of these findings to other ethnic groups should be done with
caution.
Conclusions
Current vitamin D status was associated with circulating
concentrations of tPA and D-dimer, which may suggest a role
for vitamin D in maintaining antithrombotic homeostasis. Further
studies, including randomised controlled trials, are needed to
demonstrate the role of vitamin D metabolism in cardiovascular
health, and whether vitamin D supplementation or improved
vitamin D status could have beneficial effects.
Methods
Written consent for the use of information in medical studies
was obtained from the cohort members. The 45y biomedical
survey of the 1958BC was approved by the South-East Multi-
Centre Research Ethics Committee (ref: 01/1/44).
Participants in this study are from the 1958 British birth cohort,
which included all births in England, Scotland, and Wales during
one week in March 1958 (n=17,416) [41,42]. Between September
2002 and April 2004 a target population of 11,971 individuals
currently living in Britain were contacted aged 44y (31.1%) to 46y
(0.4%): 78% (n=9377) participated in the biomedical survey and
7591 (80%) also provided blood samples from which 25(OH)D
was measured [19,42]. This sample is representative of the
surviving cohort; however, as we have reported previously, there is
some under-representation of specific minority groups [41]. The
1958BC is largely a white European population (98%); for these
analyses 154 individuals of other ethnicity groups were excluded.
We further excluded one participant who was pregnant at the time
of survey. As the main focus of the analyses was to evaluate the
association of 25(OH)D concentrations on pre-clinical alterations
in inflammatory and hemostatic markers, we excluded all
participants (n=532) who used any type of medication used to
treat cardiovascular problems (BNF code 2: Cardiovascular
systems). We further excluded participants with missing data on
BMI or inflammatory/hemostatic markers (n = 366) leaving 6538
individuals for the main analyses.
Laboratory analyses
Venous blood samples were obtained without prior fasting and
posted to collaborating laboratories. Fibrinogen was determined
by the Clauss method and CRP assayed by nephelometry (Dade
Behring) on citrated plasma samples after one thaw cycle. vWF
antigen was measured by Decollates enzyme-linked immunosor-
Figure 3. Seasonal variation in C-reactive protein (A), fibrino-
gen (B), D-dimer (C), tissue plasminogen activator (D), and von
Willebrand factor (E). Values are from the partial regression of the
harmonic components; Model 1 (solid line) adjusted for respiratory
infections, alcohol consumption, PC/TV time, physical activity and social
class at birth and adulthood, and Model 2 (dashed line, shown with 95%
confidence intervals) in addition to above adjusted for 25-hydroxyvi-
tamin D. Tick marks denote average concentrations (SDS, predicted
from random effects models) with 95% confidence intervals shown by
error bars. Predicted means for CRP from linear models, no seasonal
pattern observed (p.0.8). *p-values from the product of coefficient
mediation test used to assess the 25(OH)D mediation effect on the
seasonal patterns in the outcomes.
doi:10.1371/journal.pone.0010801.g003
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bent assay (elisa) and tPA antigen by Biopool elisa. 25(OH)D was
measured using automated application of the IDS OCTEIA elisa
on the Dade-Behring BEP2000 analyser (sensitivity of 5.0 nmol/l,
linearity #155 nmol/l, intra-assay variation CV 5.3–7.4% and
inter-assay variation CV 7.7–8.5%) [41,43]. Heterogeneity of
25(OH)D concentrations measured by different assays is well-
known, therefore levels were standardized according to the mean
of the Vitamin D External Quality Assessment Scheme (DEQAS)
[43].
Demographic, lifestyle and social factors have been described in
detail previously [19,42,44,45,46]. In brief, weight, height and
waist circumference were measured at 45y. Socio-economic
position at birth (1958) and at age 42y was assessed using the
Registrar General’s occupational classification categorised as I &II
(professional/managerial), III non-manual, III manual, IV & V
(unskilled manual) [44]. Recreation Metabolic Equivalent of Task
(MET) hours per week at 45y was derived from reported
frequencies and usual durations for up to 37 activities, and
published MET scores. We divided recreational activity into
gender-specific quartiles. An additional category was created for
implausibly high values (participants with weekly recreation hours
of 3 standard deviations (SD) above the gender mean). Participants
engaging in vigorous activity were those who recorded an activity
with a MET score greater than six. Time spent watching a
television or using a computer was reported at age 45y [19].
Information on smoking was based on smoking history recorded at
ages 23y, 33y and 42y [46] and alcohol consumption on report
from age 45y.
Statistical Analysis
To describe the distribution of 25(OH)D concentration we used
dichotomous indicators for levels below 25 nmol/l and above
125 nmol/l and a categorised factor into 25 nmol/l divisions with
minimum ,25 nmol/l and maximum $125 nmol/l tails. The
natural logarithmic transformation was used to calculate geometric
means to adjust the skewed distribution.
Inflammatory and hemostatic markers were transformed to
gender-specific standard deviation scores (SDS) to compare
variation across models. The SDS values were used as response
variables in linear mixed effects regression models. Initial analyses
included validation and graphical examination of data, statistical
evaluation of linear and quadratic terms for 25(OH)D, adiposity
measures (BMI and waist circumference), and single and joint
effects of these measures on the inflammatory/hemostatic
outcomes. Continuous measures were used in testing for
interactions between the adiposity measures and 25(OH)D on
the outcomes. For D-dimer three outlying observations were
identified from graphical examination and model diagnostics
(leverage and/or influence .2SD), and excluded from further
analysis. We fitted linear regression models in three stages, starting
with simple associations between 25(OH)D (categorized into
10 nmol/l groups, minimum ,25 nmol/l and maximum
$125 nmol/l tails) and the SDS inflammatory/hemostatic
outcomes (model 1), next adjusting in addition for demographic,
lifestyle and social factors (model 2), and finally adjusting for
adiposity in addition to lifestyle and social factors (model 3).
Models (1–3) included covariates gender and month of measure-
ment and models with fibrinogen SDS as the outcome included
laboratory assay batch. We also created an additional 25(OH)D
category variable of ,25, 25–74.9 and $75 nmol/l to summarize
the effect size and repeated analyses for model 3. Missing
information on the lifestyle factors (n=514 with missing
information on one or more factors) was imputed using the
multiple imputation chained equations [47]. The models (1–3)
were run on 10 imputed datasets and repeated for the sample
restricted to participants with complete data on all confounders.
The results were similar with both approaches; hence, results are
only presented from the imputed models.
Seasonal variations were modeled using sine and cosine
functions [48] with laboratory assay batch as a random effect on
the intercept where appropriate (Likelihood Ratio Test (LRT) on



















Where Y is the response variable, i denotes the individual within
the assay batch j , T is the time period (T=365 days), nc is the
number of seasonal patterns with sequence (nc~ 1,2,3f g) or
combination of them, pk is the period for the season (pk~ 1,2,4f g)
where 1ƒtƒT , Xi3 is a matrix of linear predictors for the vector
of parameters b3 (inclusive of the mediator variable and seasonal
confounders). The random effect in the intercept, m0j , is defined by
the laboratory assay batch as the dates of the blood samples were
associated with the assay batches and we did not wish to estimate
the effect of batch on the response; we assume m0j,N 0,s2m
 
.
Finally, the observational error terms eijt were assumed to be
normally distributed with mean 0 and variance s2e .
Without the hierarchical structure implied by the random
effects terms we may have under-estimated the standard error on
the intercept. The nc seasonal patterns investigated were yearly,
half yearly, quarterly, and all their combinations of were included
if appropriate. Models were adjusted for the potential seasonal
confounders of respiratory infections, alcohol consumption,
PC/TV time, physical activity and social class at birth and
adulthood. These resulting models were further adjusted for
25(OH)D, its dominant yearly pattern and then re-tested for
subsidiary cycles.
To quantify the seasonal effect of 25(OH)D on the outcomes we
used the concept of mediation analysis [47,49] where season, as
modeled with the sine/cosine transformation, was the independent
variable and 25(OH)D acted as its mediator to the outcomes. The
product of coefficients test [50] used in mediation analysis was
extended to allow for the amplitude (the seasonal variation around
the mean) as derived from the sine/cosine transformation. The
final seasonal models predict the mean levels of the outcomes from
the partial regression coefficients of the seasonal functions. All
analyses were carried out using STATA, version 10.0 (StataCorp
LP, College Station, TX).
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